
|Videos|April 28, 2022
Tarsus pipeline advances program for Demodex blepharitis
Author(s)Kassi Filkins
Last year, the company announced the data from the Saturn-1 study for TP-03, the first potential product to treat Demodex blepharitis, and the product is now in the phase 3 trial (Saturn-2). Aziz Mottiwala, chief commercial officer for Tarsus, gives a company update on the pipeline for their program for Demodex blepharitis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Recognizing biomarkers of Alzheimer Disease using OCTA
2
Midyear cataract check-in: What 2026 has brought to the OR and beyond
3
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5




















